Stock MIRA MIRA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company MIRA Pharmaceuticals, Inc.

Equities

MIRA

US60458C1045

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 02:00:00 29/05/2024 am IST 		5-day change 1st Jan Change
0.8501 USD -3.94% Intraday chart for MIRA Pharmaceuticals, Inc. -16.66% -19.04%
20/05 Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, A Differentiated Oral Ketamine Analog CI
13/05 MIRA Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

MIRA Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical development company. The Company has two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2, a patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDSI) and potentially post-traumatic stress disorder (PTSD). Its oral pharmaceutical marijuana molecule, MIRA-55, is being studied for its potential to alleviate neuropathic pain, as well as anxiety and cognitive decline, symptoms commonly associated with early-stage dementia.

Managers

Managers TitleAgeSince
Erez Aminov CEO
 Chief Executive Officer 46 01/23/01
Michelle Yanez DFI
 Director of Finance/CFO 52 01/22/01

Members of the board

Members of the board TitleAgeSince
Dave Vorhoff
- -
Michael Jerman BRD
 Director/Board Member 40 14/11
Erez Aminov CEO
 Chief Executive Officer 46 01/23/01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 14,780,885 10,478,415 ( 70.89 %) 0 70.89 %

Shareholders

NameEquities%Valuation
George Cappy
18.54 %
2,740,270 18.54 % 2 M $
William J Nellis
4.601 %
680,000 4.601 % 612 000 $
Brian McNulty
4.533 %
670,000 4.533 % 603 000 $
Cross Staff Investments, Inc.
2.594 %
383,401 2.594 % 345 061 $
Erez Aminov
2.586 %
382,200 2.586 % 343 980 $
Christopher Chapman
1.353 %
200,000 1.353 % 180 000 $
Adam Kaplin
1.353 %
200,000 1.353 % 180 000 $
Virtu Financial LLC
0.4266 %
63,055 0.4266 % 56 750 $
Brad Kroenig
0.3383 %
50,000 0.3383 % 45 000 $
Hugh McColl
0.2706 %
40,000 0.2706 % 36 000 $

Company contact information

MIRA Pharmaceuticals, Inc.

1200 Brickell Avenue Suite 1950 1183

33131, Miami

+786-432-9792

http://mirapharmaceuticals.com
address MIRA Pharmaceuticals, Inc.(MIRA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MIRA PHARMACEUTICALS, INC. Stock MIRA Pharmaceuticals, Inc.
-19.04% 1.26Cr
MODERNA, INC. Stock Moderna, Inc.
+54.05% 5.87TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.02% 4.13TCr
LONZA GROUP AG Stock Lonza Group AG
+40.01% 3.92TCr
CELLTRION, INC. Stock Celltrion, Inc.
-10.22% 2.74TCr
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.42% 2.65TCr
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.60% 1.9TCr
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+2.89% 1.25TCr
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+22.40% 1.19TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.49% 1.21TCr
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MIRA Stock
  4. Company MIRA Pharmaceuticals, Inc.